You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
BOSTON , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10 th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021 . A live webcast of the presentation will be available
BOSTON , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m.
17% growth in January 2021 for new TYMLOS® patients vs. previous 4 month trailing average Histomorphometry study published: Journal of Bone & Mineral Research in January 2021 Cardiovascular safety study published: Journal of Clinical Endocrinology & Metabolism in November 2020 Japan : with our
BOSTON , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health , Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 at 9:10 a.m. EST .
RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases Prader-Willi syndrome (“PWS”) will be the initial indication, which has been granted Orphan Drug and Fast Track Designation by the FDA Acquisition and
Agreement incorporates TYMLOS ® and abaloparatide-TD Consideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royalties Key first step in expanding the global footprint for the abaloparatide asset beyond the U.S.
BOSTON , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the Company’s board of directors. Ms. Sanders and Dr. von Eschenbach will fill vacancies created by the
Continued growth in net new patients for the month of November 2020 Company is on-track for record quarter in net revenue for TYMLOS-SC Research Agreement reached with MGH in October 2020 Hired Head of Clinical Development for the abaloparatide molecule WALTHAM, Mass. , Dec.
TYMLOS ® U.S. net sales of $50 million with 8% year-over-year growth; Total Revenues of $78 million Q3 commercial pivot to focus on high risk fracture segment is gaining traction: Net New U.S. Patients increased by 7+% in September 2020 vs. previous 3-month moving average and 10 +% in October vs.
Completed e nrollment in 3 p ivotal c linical t rials; multiple data read outs in Q4 2021 Released meaningful abaloparatide histomorphometry data at recent ASBMR meeting Completed two business development transactions with existing oncology asset s Repositioned commercial effort to focus on high